Physician

Patrick P Litam, MD

According to 2025 Medicare claims, Patrick Litam, MD (NPI: 1447203054) practices hematology/oncology in the Cleveland, OH market, with the plurality of this provider's patient population coming from Lorain, OH. This provider's primary affiliated billing organization is AMERICAN ONCOLOGY PARTNERS PA (NPI: 1265929723; TIN: 824681345) and primary practice location at 44035-2249. Litam is affiliated with the Mercy Health Select, LLC (ACO ID: A1215), participating under the MSSP model.

Litam's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 534 traditional Medicare patients, billed 61,548 HCPCS/CPT codes, and received $1,695,958 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 1,400 prescription claims across 287 beneficiaries totaling $5,521,036 in drug costs, led by Pomalyst (Pomalidomide). DME data shows 23 claims. Open Payments data shows 81 records totaling $1,803. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $1,117,363 and ending at $1,695,958. Concurrently, Part D prescription costs have risen steadily, from $1,764,242 to $5,521,036. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	897	108,308	$1,117,363
2016	937	110,540	$1,236,832
2017	856	102,683	$1,184,213
2018	725	124,845	$1,311,338
2019	561	65,617	$635,873
2020	574	93,470	$966,082
2021	434	106,857	$1,057,317
2022	429	46,564	$630,719
2023	595	80,406	$1,086,676
2024	534	61,548	$1,695,958

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	301	1,326	$1,764,242
2016	312	1,387	$2,175,975
2017	298	1,269	$1,942,937
2018	309	1,171	$2,476,985
2019	296	1,212	$2,858,582
2020	217	1,029	$2,489,755
2021	212	1,136	$2,972,562
2022	178	1,025	$2,820,555
2023	271	1,243	$3,931,680
2024	287	1,400	$5,521,036

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	127	$78,815
2016	N/R	45	$12,109
2017	N/R	31	$5,247
2018	N/R	N/R	N/R
2019	N/R	25	$2,323
2020	N/R	44	$3,341
2021	N/R	31	$1,510
2022	N/R	23	$466
2023	N/R	28	$6,588
2024	N/R	23	$606

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	72	72	$110
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	179	339	$91
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	306	409	$57
36415	Insertion of needle into vein for collection of blood sample	450	1,224	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	449	1,210	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Pomalyst	Pomalidomide	50	1,400	$1,126,989
Revlimid	Lenalidomide	93	2,324	$1,000,125
Cabometyx	Cabozantinib S-Malate	21	630	$543,655
Xtandi	Enzalutamide	20	600	$284,157
Tabrecta	Capmatinib Hydrochloride	12	336	$274,541

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	11	$380
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	12	$226

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	81	$1,803	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Patrick P. Litam, MD?

Tedicare shows public-source Medicare data for Patrick P. Litam, MD (NPI 1447203054), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Patrick P. Litam, MD have ACO affiliation data?

Patrick P. Litam, MD is shown with ACO affiliation data for Mercy Health Select, LLC (MSSP, ACO ID A1215).

What billing organization is linked to Patrick P. Litam, MD?

Patrick P. Litam, MD is linked to AMERICAN ONCOLOGY PARTNERS PA (billing NPI 1265929723) in the available physician profile data.

Does Patrick P. Litam, MD have Open Payments data?

Patrick P. Litam, MD has 81 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.